Home > Insider Trading > Filing (0001567619-21-019360)

Filing Details

Accession Number:: 0001567619-21-019360
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-11-04 19:10:42
Reporting Period:: 2021-11-02

Accepted Time:: 2021-11-04 19:10:42
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1770787	10X Genomics Inc.	TXG	Laboratory Analytical Instruments (3826)	455614458

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1786720	Serge Saxonov	C/O 10X Genomics, Inc. 6230 Stoneridge Mall Road Pleasanton CA 94588	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Class A Common Stock	Acquisiton	2021-11-02	5,208	$5.04	897,344	No	4	M	Direct
Class A Common Stock	Acquisiton	2021-11-02	3,037	$11.48	900,381	No	4	M	Direct
Class A Common Stock	Disposition	2021-11-02	3,241	$160.26	897,140	No	4	S	Direct
Class A Common Stock	Disposition	2021-11-02	5,946	$161.06	891,194	No	4	S	Direct
Class A Common Stock	Disposition	2021-11-02	5,613	$161.94	885,581	No	4	S	Direct
Class A Common Stock	Disposition	2021-11-02	200	$163.14	885,381	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Stock Option (right to buy)	Disposition	2021-11-02	5,208	$0.00	5,208	$5.04
Class A Common Stock	Stock Option (right to buy)	Disposition	2021-11-02	3,037	$0.00	3,037	$11.48

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
58,532		2028-11-02	No	4	M	Direct
51,633		2029-05-10	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Class A Common Stock	4,498	Indirect	See footnote
Class A Common Stock	89,960	Indirect	See footnote

Footnotes

The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $159.60 to $160.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $160.60 to $161.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $161.63 to $162.53. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
This option, originally for 250,000 shares, of which 191,468 have been exercised, vested as to 1/48th of the shares on October 1, 2018, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
This option, originally for 145,786 shares, of which 94,153 have been exercised, vested as to 1/48th of the shares on May 1, 2019, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.